INOVIO's VOCERYQ received accelerated FDA approval to reduce surgeries in adults with recurrent respiratory papillomatosis (RRP), marking the first FDA-approved DNA medicine. The therapy targets the root cause of RRP and is expected to be commercially available by early 2027. INOVIO raised $80.5 million to support VOCERYQ's launch and plans confirmatory studies and European approval submissions. This milestone validates INOVIO's DNA medicine platform and supports further pipeline development.
Inovio Pharmaceuticals Inc has a market cap of $167.31 million and a daily trading volume of 31,110,328 shares on Pluang as of Nov 11, 2026 04:02 WIB. The stock price is currently $1.44, down 4.64% in the last day, while order activity shows 72% of trades are buys. This trading activity occurs alongside the recent FDA approval of INOVIO's VOCERYQ, highlighting investor interest in the company's DNA medicine platform.
